Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222833 | 0.93 | HPGD (0.47) | HPGDRORCALDH1A1KDM4EKMT2A | |
| SCHEMBL7231130 | 0.92 | KMT2A (0.40) | HPGDRORCALDH1A1KDM4EKMT2A | |
| SCHEMBL7229260 | 0.84 | ALDH1A1 (0.38) | RORCALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL7224270 | 0.81 | NR1I2 (0.46) | RORCALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL7223946 | 0.80 | CYTH2 (0.46) | HPGDALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL7229122 | 0.78 | CYP3A4 (0.42) | RORCALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL7221394 | 0.78 | CYP2C9 (0.37) | HPGDALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL7221678 | 0.77 | CYTH2 (0.56) | HPGDALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL7224044 | 0.77 | CYP17A1 (0.35) | MAPTPGR | |
| SCHEMBL7224301 | 0.77 | KMT2A (0.50) | HPGDALDH1A1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | COLLONGES FRANCOIS (FR) | 2003-10-30 | — | — | US | claimed |
| US-6509499-B1 | Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-01-21 | — | — | US | claimed |
| EP-0946503-B1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 2002-03-27 | — | — | EP | claimed |
| EP-0946503-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GmbH (DE) | 1999-10-06 | — | — | EP | claimed |
| WO-1998028265-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 1998-07-02 | — | — | WO | claimed |
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | COLLONGES FRANCOIS (FR) | 2003-10-30 | — | — | US | disclosed |
| US-6509499-B1 | Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-01-21 | — | — | US | disclosed |
| EP-0946503-B1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 2002-03-27 | — | — | EP | disclosed |
| EP-0946503-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GmbH (DE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028265-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | AKR1B1, ALDOA, AKR1C1 | HPGD 238/4885RORC 2244/4885ALDH1A1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.